The government is in talks with U.S. health care conglomerate Johnson & Johnson about securing allocations of its potential COVID-19 vaccine as the company prepares to kick off human trials, the firm's Chief Financial Officer Joseph Wolk said in an interview.
More than a hundred vaccines are under development to try and stop the COVID-19 pandemic, and drugmakers including J&J are working to ramp up their supplies of their vaccines in the face of unprecedented demand.
J&J has already agreed to prioritize an allocation to the United States as part of its funding agreement with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA), Wolk said.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.